|
Originally published In Press as doi:10.1074/jbc.M004953200 on August 15, 2000
J. Biol. Chem., Vol. 275, Issue 45, 35028-35033, November 10, 2000
Permeabilization via the P2X7 Purinoreceptor Reveals
the Presence of a Ca2+-activated Cl
Conductance in the Apical Membrane of Murine Tracheal Epithelial
Cells*
Sherif E.
Gabriel §,
Mariya
Makhlina ,
Elena
Martsen ,
Emma
J.
Thomas¶,
Mike I.
Lethem¶, and
Richard C.
Boucher
From the Cystic Fibrosis/Pulmonary Research and
Clinical Treatment Center, University of North Carolina, Chapel
Hill, North Carolina 27599 and the ¶ School of Pharmacy and
Biomolecular Sciences, University of Brighton, Brighton BN2 4GJ, United
Kingdom
Received for publication, June 7, 2000, and in revised form, August 8, 2000
 |
ABSTRACT |
Calcium-activated Cl
secretion is an important modulator of regulated ion transport in
murine airway epithelium and is mediated by an unidentified
Ca2+-stimulated Cl channel. We have
transfected immortalized murine tracheal epithelial cells with the
cDNA encoding the permeabilizing P2X7 purinoreceptor (P2X7-R) to selectively permeabilize the basolateral
membrane and thereby isolate the apical membrane
Ca2+-activated Cl current. In
P2X7-R-permeabilized cells, we have demonstrated that UTP
stimulates a Cl current across the apical membrane of CF
and normal murine tracheal epithelial cells. The magnitude of the
UTP-stimulated current was significantly greater in CF than in normal
cells. Ion substitution studies demonstrated that the current exhibited
a permselectivity sequence of Cl > I > Br > gluconate . We have
also determined a rank order of potency for putative Cl
channel blockers: niflumic acid 5-nitro-2-(3-phenylpropylamino)benzoic acid > 4,4'-diisothiocyanostilbene-2,2'-disulfonate > glybenclamide diphenlyamine-2-carboxylate, tamoxifen, and
p-tetra-sulfonato-tetra-methoxy-calix[4]arene. Complete characterization of this current and the corresponding single
channel properties could lead to the development of a new therapy to
correct the defective airway surface liquid in cystic fibrosis patients.
 |
INTRODUCTION |
Chloride secretion across the airway epithelium can be stimulated
by a number of secretogogues that activate distinct second messenger
transduction mechanisms (reviewed in Refs. 1 and 2). The cystic
fibrosis (CF)1 gene product,
the cystic fibrosis transmembrane conductance regulator (CFTR),
accounts for the cAMP-regulated apical Cl conductance (3,
4). There is, however, compelling evidence that a separate
Ca2+i-activated apical Cl conductance
(CaCC) exists. A large class of ligands, including histamine (5, 6),
bradykinin (7, 8), and extracellular ATP (9-11), has been shown to
activate CaCC across the apical membrane of airway epithelia. The
unique identity of this pathway in airway epithelia was established in
studies of CF nasal epithelia, which demonstrated that Ca2+
ionophores are effective Cl secretogogues in CF tissues
(12-14). Moreover, in the airways of the CFTR( / ) knockout mouse,
which definitively lacks CFTR (15), not only is the CaCC pathway
preserved, but it appears to be up-regulated (16).
In the airway epithelium, Cl secretion is dependent on
the development of a favorable driving force, because at basal
conditions Cl is at or near electrochemical equilibrium
across the apical membrane. Ca2+i can stimulate
Cl secretion by multiple mechanisms. Elevation of
Ca2+i can directly activate an apical
membrane-localized Cl conductance and thereby stimulate
an apical exit pathway for Cl secretion. Ca2+
mobilizing agents can also cause a hyperpolarization in the cell to
generate a driving force for Cl secretion across the
apical membrane by either (or both) inhibiting an apical membrane
Na+ conductance (17) or activating a basolateral
K+ conductance. Thus study of
Ca2+i-activated Cl conductance in the
apical membrane of a polarized epithelium requires a means to identify
the contributions of apical Cl conductance in isolation
from other actions.
Previous studies in non-polarized secretory epithelia, e.g.
airway epithelia or T84 cells plated as isolated or
dissociated cells, have shown outwardly rectifying Cl
currents stimulated by intracellular Ca2+ and sensitive to
4,4'-diisothiocyanostilbene-2,2'-disulfonate (DIDS) (18-24). These
descriptions have included such a wide range of Cl
channel characteristics that no consensus on the characteristics of
this channel can be achieved (25-28). Recently, a family of putative
CaCC genes has been cloned (29-32). The single channel properties and
the cellular localization of these gene products, however, have not yet
been determined. Thus, no indisputably apical Ca2+-activated Cl channel has been identified
at either the molecular or single channel level.
We have recently identified a CaCC current expressed in immortalized CF
and normal murine tracheal epithelial cell lines (33). In the current
study we used permeabilization of the basolateral membrane to determine
the basic biophysical properties of the CaCC current in a functionally
isolated apical membrane of airway epithelial cells. We have
accomplished basolateral permeabilization by a novel approach involving
stable transfection of the P2X7 purinoreceptor
(P2X7-R) into our murine CF tracheal epithelial cell line.
The P2X7-R is unique within its family, because binding of
nucleotides (ATP4 is the preferred agonist) to this
receptor results in the formation of a membrane pore that is capable of
conducting molecules as large as 900 daltons (34, 35). The pore is not
ion-selective and allows for free diffusion of both cations and anions.
Thus, by application of ATP selectively to the basolateral solution, we
can selectively permeabilize this barrier.
We report here the characterization of CaCC in the apical membrane of a
CF tracheal epithelial cell line when activated by different classes of
Ca2+i-mobilizing agents (UTP and ionomycin). We
have determined the halide selectivity and inhibitor sensitivity of
this Cl current unambiguously localized to the apical
membrane. Importantly, these observations will provide us with the
hallmark characteristics for comparison with subsequent whole cell and
single channel studies and will enable us to evaluate CaCC candidate
genes. A greater understanding of the characteristics and mechanism of
regulation of the CaCC pathway is essential for development of
pharmacological therapies designed to use CaCC as an alternate
Cl channel to replace the defective CFTR.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
These studies utilized the immortalized murine
tracheal epithelial cell line (MTE18) derived from the CFTR( / )
knockout mouse, described previously (33). Cells were maintained and
cultured at 33 °C, the permissive temperature for the immortalizing
tsA58 TAg activity (33) on "Transwell-col" culture inserts. Culture medium consisted of a 1:1 mix of Ham's F12 and 3T3
fibroblast-conditioned medium supplemented with the following hormones:
transferrin (2.5 mg/ml), insulin (5 mg/ml), epidermal growth factor
(12.5 ng/ml), endothelial cell growth supplement (1.875 mg/ml),
triiodothyronine (15 nM), hydrocortisone (0.5 mM), and CaCl2 (0.5 mM). Cells were harvested for experimental studies by trypsinization and plated at high
density (2 × 104 cells per mm2) onto
tissue culture inserts (collagen matrix supports with a 4.5-mm plating
diameter) and evaluated for confluence by daily monitoring of
transepithelial resistance (RT) and potential
difference (VT). Only monolayers generating at
least a 1.0-millivolt (mV) VT and a
100- ·cm2 resistance (after the resistance of the
permeable support is subtracted) were used for Ussing chambers studies,
typically 5-7 days after plating.
Ussing Chamber Studies--
Electrical measurements,
i.e. VT, RT,
and short-circuit current (ISC), were made on
cell monolayers mounted in Ussing chambers. Monolayers were bathed in a
Krebs bicarbonate Ringer solution (KBR) on both the lumenal and the
serosal sides. Serosal Ca2+ was buffered to 300 nM with the addition of EGTA (achieved by the addition of 1 mM EGTA and 0.925 mM Ca2+). Other
alterations to the bathing solutions are listed in the figure legends.
All bathing solutions were bubbled with 95% O2, 5%
CO2 and maintained at 37 °C. VT
was clamped to zero and pulsed to ±10 mV for a 0.5-s duration every
minute. Electrometer output was digitized online and
ISC, RT, and calculated
transepithelial potential (VT) were displayed on
a video monitor and stored on a computer hard drive. Drugs were added
from concentrated stock solutions to either lumenal and/or serosal
sides of the tissue. To eliminate the contribution of apical
Na+ channels, amiloride (10 4 M)
was added to the lumenal bath at the outset of all experiments. Data
are expressed as mean ± S.E. for the number of experiments (n). Student's t test was used to determine
statistical significance between means.
Permeabilization--
Basolateral membrane permeabilization was
achieved by stable transfection of the recombinant P2X7-R
(a generous gift from Dr. George Dubyak) into the MTE18 cell line. A
cDNA construct of the P2X7-R was cloned into a
retroviral expression vector with a selectable puromycin-resistance
gene. Infection of the MTE18 cell line with this retroviral vector and
selection of resistant colonies in puromycin-containing media resulted
in the identification of several cell clones that were
puromycin-resistant and were verified for expression of
P2X7-R. These P2X7-R-expressing cells were
plated on membrane supports and used for Ussing chamber studies.
Following recording of stable baseline ISC and
RT (15-20 min in symmetrical Cl
KBR solutions), 1 mM ATP4 (UTP is not an
agonist for the P2X7-R) was added to the serosal solution
and serosal Mg2+ was reduced to 100 µM to
activate the pore (divalent cations inhibit pore formation). Following
successful permeabilization, documented by a drop in the
ISC to 0 µA/cm2, the lumenal
solution was diluted by three successive 1-ml replacements of KBR with
a low Cl containing (4.8 mM Cl ,
110 mM gluconate ) KBR. This maneuver
generates a gradient for Cl secretion with a serosal
Cl concentration of 115 mM and a final
lumenal Cl concentration of 68 mM.
Ca2+i-mobilizing agents were added to the lumenal
solution after the final dilution step. Anion selectivity was
determined by a similar strategy used to generate the Cl
gradients. Briefly, three successive 1-ml replacements of the lumenal
solution with a modified KBR solution containing a halide ion
(I , Br ) were substituted for
Cl (e.g. 4.8 mM Cl ,
110 mM I ). The inhibitor profile of CaCC was
determined by the addition of inhibitors to the lumenal solution after
the imposition of the Cl gradient and prior to
stimulation by UTP. All experiments consisted of alterations in the ion
composition of the mucosal or serosal solution, followed by CaCC
activation by addition of lumenal UTP.
In a subset of experiments we used the -toxin of
Staphylococcus aureus to permeabilize MTE18 or MTE7b
(CFTR(+/ ) cells) monolayers not expressing the P2X7-R.
1000 units of -toxin was introduced to the serosal compartment
bathing MTE18 or MTE7b monolayers and monitored for ~60 min until the
ISC dropped to 0 µA/cm2,
indicating permeabilization. Subsequent dilutions and agonist additions
were performed as described for P2X7-R monolayers.
Data Analysis--
In CF and normal airway epithelial cells,
mucosal nucleotides, ATP or UTP, acting via purinergic receptors cause
an increase in ISC by reducing the apical
membrane resistance with little or no effect on the basolateral or
shunt resistance, i.e. by directly activating an apical
membrane conductance (11). All experiments were performed under voltage
clamp conditions (clamped to 0 mV) and in the presence of a
Cl gradient followed by the addition of mucosal UTP. Our
experimental protocol defines the CaCC current as
ICaCC = IUTP Igradient. Because the transepithelial potential
is clamped to 0 mV, the equilibrium potential for Cl can
be calculated as ECl = ICaCC GCaCC and is determined
by the chemical driving force imposed as a result of the
Cl gradient. This measured
ECl should ideally
equal the calculated ECl
determined by the Nernst equation. We used the measured
Eion (Cl , Br ,
I ) values to determine a permselectivity sequence.
Apparent differences between the measured Eion
and Nernst equation-calculated Eion values are
likely caused by ion permeation and accumulation in the unstirred layer
closely adjacent to the membrane surface (37).
Materials--
All biochemicals used were obtained from
commercial sources and were of tissue culture grade or better.
 |
RESULTS |
Transfection and expression of P2X7-R in MTE18 cells
followed by incubation of monolayers with 1 mM ATP and 10 µM ToPro-1-iodide (a membrane-impermeant dye that
fluoresces when bound to DNA, Mr = 645)
demonstrates efficient membrane permeabilization (Fig. 1). Although cells exposed to ATP for
either 10 or 30 min showed distinct intracellular fluorescence (Fig. 1,
right two panels), P2X7-R-expressing cells not
exposed to ATP showed no significant fluorescence beyond background
levels (Fig. 1, left two panels). Control MTE18 cells or
MTE18 cells expressing the control LISN vector, did not show any
intracellular fluorescence in response to a 30-min exposure with 1 mM ATP (data not shown). We used this cell line (murine
tracheal CFTR( / ) epithelial cells, expressing P2X7-R)
and selective permeabilization of the basolateral membrane to
characterize CaCC resident in the apical membrane of airway epithelial
cells.

View larger version (97K):
[in this window]
[in a new window]
|
Fig. 1.
ATP-mediated permeabilization of the
basolateral membrane of P2X7-R monolayers.
P2X7-R-expressing cells were exposed to 10 µM
ToPro-1-iodide in the absence (left two panels) or presence
(right two panels) of 1 mM ATP for 10 or 30 min.
Cells were photographed on a fluorescence inverted microscope with
identical exposure times.
|
|
Basolateral membrane permeabilization of murine tracheal epithelial
cells followed by imposition of a Cl gradient and
activation by mucosal UTP revealed the presence of an apical membrane
Cl current (Fig. 2).
Application of a cell to lumen Cl gradient resulted in a
greater response in monolayers exposed to serosal 1 mM ATP
than to cells not permeabilized by ATP (Fig. 2B, 34.4 ± 9.2 versus 7.5 ± 2.4 µA/cm2).
Importantly, addition of mucosal UTP to permeabilized cell monolayers
was still capable of stimulating an increase in
ISC consistent with Cl secretion
(Fig. 2A, solid line trace, and Fig.
2B, right panel, filled bar). Similar
responses to both an imposed Cl gradient and mucosal UTP
addition ( ISC = 54 ± 7.4 and 32.1 ± 8.9 µA/cm2, n = 8, respectively) were
observed in MTE18 (CF) monolayers permeabilized by S. aureus
-toxin. The magnitude of the Cl secretory response to
the purinergic agonist UTP was significantly greater in
-toxin-permeabilized MTE18 preparations than in
-toxin-permeabilized MTE7B (normal) preparations (32.1 ± 8.9 µA/cm2, n = 8; 10.9 ± 3.7 µA/cm2, n = 8, respectively,
p < .001). Elevation of intracellular Ca2+
by inclusion of the ionophore, ionomycin (1 µM), showed a
similar ability to stimulate Cl secretion in
permeabilized CF monolayers (25.8 ± 6.6 µA/cm2,
n = 8).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2.
Characteristic CaCC current response in
P2X7-R permeabilized MTE18 monolayers. A,
typical ISC responses in
P2X7-R-expressing MTE18 monolayers permeabilized by 1-mm
serosal ATP (solid line) and non-permeabilized MTE18
monolayers (dashed line). Both permeabilized and
non-permeabilized monolayers were treated similarly during the rest of
the experimental protocol. Lumenal Cl was successively
diluted by replacement with a sodium gluconate solution to achieve a
final lumenal Cl concentration of 68 mM, and
10 µM UTP was added to the lumenal solution (as indicated
by the arrows). B, mean Cl current
responses in permeabilized (filled bars) and
non-permeabilized (open bars) MTE18 monolayers. Gradient
responses (left two bars) represent the total
ISC response following the final solution
change. The ISC in response to UTP (10 µM) addition following the imposition of the
Cl gradient is shown in the right two bars.
Filled bars represent the mean current response of
P2X7-R monolayers exposed to serosal ATP (permeabilized,
n = 13), and open bars represent
P2X7-R monolayers in the absence of serosal ATP
(non-permeabilized, n = 14). Values represent mean and
S.E. for each condition.
|
|
We have used several solution changes to verify that the observed
current in MTE18-P2X7-R cells is a Cl
current. As shown above (Fig. 2) Cl secretion (serosal to
mucosal) is stimulated by imposition of a chemical gradient
(i.e. lower Cl concentration in the lumenal
solution). Reversal of this gradient, by decreasing the serosal
Cl concentration in permeabilized preparations, results
in stimulation of "Cl absorption" (mucosal to
serosal) (Fig. 3). When the
Cl concentration in the lumenal solution was maintained
at 115 mM and the serosal solution was sequentially
reduced, an absorptive Cl current was recorded (Fig.
3A). The magnitude of the response was similar to the
response observed for Cl secretion (Fig. 2) but in the
opposite direction (68.8 ± 7.4 versus 54.1 ± 8.2 µA/cm2, respectively). Mucosal UTP was likewise able to
augment this basal level of Cl absorption by
18.2 ± 15.8 µA/cm2. MTE18-P2X7-R cells
that were not permeabilized (not exposed to serosal ATP) did not
respond to the imposed absorptive gradient (data not shown).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 3.
Effects of altering the Cl
gradient in P2X7-R monolayers. A, dilution
of the serosal Cl concentration generates a mucosal to
serosal Cl current. All bars represent
P2X7-R monolayers permeabilized by 1 mM serosal
ATP. Cl gradients were generated as described above
(i.e. dilution of either the lumenal or serosal solution to
achieve a Cl concentration ratio of 115 mM to
68 mM). Filled bars (n = 10)
represent monolayers with 115 mM mucosal Cl
and 68 mM serosal Cl concentrations, and
open bars (n = 13) represent monolayers with
115 mM serosal Cl and 68 mM
mucosal Cl concentration. The response to 10 µM lumenal UTP following the generation of the
Cl gradient is shown in the right two bars.
B, Cl secretion induced with lower serosal
Cl concentrations. All conditions contain 35 mM Cl in the serosal solution and a final
mucosal Cl concentration of 20 mM.
Filled bars represent the mean current response of
P2X7-R monolayers exposed to serosal ATP (permeabilized,
n = 11), and open bars represent
P2X7-R monolayers in the absence of serosal ATP
(non-permeabilized, n = 18). The
ISC response to 10 µM lumenal UTP
is shown in the right two bars. Values represent mean and
S.E. for each condition.
|
|
We also studied the magnitude of the Cl current when the
serosal Cl concentration was reduced to levels that
approximate intracellular Cl (~35 mM). We
then imposed an outwardly directed Cl gradient by
reducing lumenal Cl to a similar ratio as previously
studied (final mucosal Cl was diluted to a value of
approximately 56% of the serosal concentration). Under these
conditions, UTP was still capable of stimulating a characteristically
similar Cl response, although the magnitude of the
response was smaller than that observed with higher Cl
concentrations (Fig. 3B).
The previous series of experiments involved dilution of the
Cl concentration by substitution with the less permeant
anion gluconate . This in effect results in a bi-ionic
permselectivity relation, which provides an opportunity to determine
the relative permeabilities of Cl and gluconate. We
subsequently performed similar experiments in which Cl
was substituted with Br or I (Fig.
4). Substitution of Cl with
gluconate showed an increase in secretory Cl current
(serosal to mucosal) as expected for a Cl dominated
current. Both bromide and iodide substitution significantly attenuated
the magnitude of this current, indicating that both of these halides,
I and Br were more permeable than gluconate
but less permeable than Cl . Simply considering the
Cl concentration on either side of the membrane, the
Nernst equation would predict an equilibrium potential of 13.6 mV.
With gluconate as the counterion, we calculated an
ECl of  9.8 mV.
When bromide was substituted for Cl , the calculated
ECl was  6.7 mV,
and when iodide was used as the counterion,
ECl was calculated to
be  3.8 mV. These increasing differences away from the Nernst
equilibrium potential describe an anion selectivity sequence that is
Cl > I > Br > gluconate .

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 4.
Halide selectivity sequence in
P2X7-R monolayers. All bars represent
P2X7-R monolayers permeabilized by 1 mM serosal
ATP and contain 115 mM serosal Cl . Mucosal
solutions were diluted to achieve a final Cl
concentration of 68 mM with the replacement anion,
gluconate (open bars, n = 11), bromide (filled bars,
n = 7), or iodide (hatched bars, n = 12). Total lumenal anion concentrations were always maintained at 115 mM (e.g. 68 mM Cl and
47 mM gluconate). Values represent mean ± S.E. for
each condition. The asterisk represents statistical
significance (p < 0.01) as determined by the
Student's t test between gluconate and bromide means and
gluconate and iodide means.
|
|
Several putative Cl channel blockers were investigated
for inhibition of UTP-stimulated Cl secretion in
P2X7-R-permeabilized MTE18 cells (Fig.
5). The most efficacious compounds
appeared to be niflumic acid (NFA) (100 µM) and
5'-nitrophenyl-propylbenzoate (NPPB; 100 µM), both of which inhibited approximately 90% of the CaCC-mediated current. The
most routinely used Cl channel blocker, DIDS (100 µM), inhibited slightly more than 60% of the
UTP-stimulated current, whereas glybenclamide (100 µM), a
K+ channel blocker that has been shown to have efficacy
against CFTR (38), blocked about 40% of the UTP-stimulated current. Finally, TS-TM calixarene (1 µM), a reported inhibitor
specific for the outward rectifying Cl channel (36), the
anti-estrogen tamoxifen (10 µM), shown to inhibit the
human ClCA2 channel (32), and diphenylamine-2-carboxylate (DPC) (100 µM) were essentially without effect (<10% inhibition) on the UTP-stimulated current.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 5.
Inhibitor effects on Cl
currents measured in P2X7-R-permeabilized monolayers.
All monolayers were permeabilized by 1 mM serosal ATP and
exposed to the serosal to mucosal Cl gradient as
described above. Inhibitors, DIDS (100 µM,
n = 8), DPC (100 µM, n = 8), glybenclamide (100 µM, n = 8), NFA
(100 µM, n = 8), NPPB (100 µM, n = 8), tamoxifen (10 µM, n = 8), and TS-TM calixarene (1 µM, n = 9) were added to the mucosal
solution prior to addition of 10 µM UTP. Values represent
mean ± S.E. of percentage inhibition of the UTP response in
comparison to permeabilized monolayers treated with vehicle alone prior
to UTP.
|
|
 |
DISCUSSION |
We have previously shown that UTP, ionomycin, and
thapsigargin are all capable of stimulating a Cl
current in both CF and normal murine airway epithelial cells (33). In
that study we demonstrated the presence of the
Ca2+-activated Cl current and noted that the
magnitude of the current was greater in CF (MTE18) than in normal
(MTE7b) cells. In this study we have used permeabilization of the
basolateral membrane to focus on an "apically isolated"
preparation. Efficacy of permeabilization is apparent by the greater
response to the imposed gradient observed in the permeabilized
versus non-permeabilized preparations (compare filled with open bars in Fig. 2B).
Dilutions of the lumenal solution in non-permeabilized monolayers leads
to only minor changes in current, but subsequent addition of UTP
generates a large change in current. In permeabilized preparations, a
large increase in current is observed in response to both changes in
the Cl concentration, as well as the addition of UTP.
Importantly, nucleotides ATP/UTP acting via the purinoreceptor,
P2Y2, have been shown to directly reduce the apical
membrane resistance with no effect on the resistance of the tight
junction (11). In our experimental design, imposition of a chemical
gradient for Cl is likely to have effects on both the
apical membrane conductance and the paracellular pathway, but
application of UTP will only stimulate Cl secretion by
activation of an apical membrane Cl channel. Thus, the
response to UTP following permeabilization and imposition of the
Cl gradient is convincing evidence for the existence of a
Ca2+i-activated apical membrane Cl
channel. Furthermore, an increase in ISC in
response to ionomycin is also confirmatory evidence that the
Ca2+i-mediated effects are the result of an apical
Cl conductance rather than an effect on the paracellular pathway.
In an intact preparation, Ca2+ activation of K+
channels in the basolateral membrane likely plays an important role in
maintaining the driving force necessary for Cl secretion.
One obvious advantage of a permeabilized preparation is that we can
eliminate the need for basolateral K+ channels by imposing
a gradient by solution changes and thereby directly focus on the apical
membrane. With these maneuvers we have shown that a
Ca2+i-activated Cl conductance is
present in the apical membrane of murine tracheal epithelial cells.
Interestingly, UTP and ionomycin regulate this apical membrane
Cl conductance even when Ca2+i is
buffered to moderate levels (300 nM) by EGTA. This suggests
that the accessory proteins necessary for regulation are not dialyzed
by permeabilization and that the mechanisms for intracellular
Ca2+ release are also well preserved. Somewhat surprising,
however, was the observation that UTP consistently activated this
Cl conductance in the presence of 1 mM EGTA.
EGTA is relatively slow in terms of buffering Ca2+ and may
not be able to rapidly chelate release from local Ca2+
stores efficiently (39, 40). This experimental protocol allows us to
buffer Ca2+ to physiological levels and preserves the
ability to observe a UTP-mediated current response. These data are
consistent with whole cell patch clamp studies that showed
ATP-activated Cl currents in human airway epithelial
cells in the presence of 10 mM EGTA (41). We have
previously shown that UTP-stimulated currents in non-permeabilized
MTE18 cells can be abolished by BAPTA-AM (33). Together, these results
suggest that the UTP-stimulated current is
Ca2+-dependent, but that released
Ca2+ is capable of activating a target before it can be
chelated by EGTA.
Heterologous expression of P2X7-R in MTE18 cells provides a
reliable, consistent, and rapid technique to generate an apically isolated preparation. Characteristically, the Cl
secretory response to the imposed Cl gradient and to the
lumenal addition of UTP is similar to the responses observed in
-toxin permeabilized monolayers. Challenging P2X7-R-expressing monolayers with ATP and the fluorescent
DNA-intercalating agent, ToPro-1-iodide, demonstrated that
P2X7-R effectively forms a pore sufficient for dialysis of
the intracellular ion solution. These studies show that nearly every
cell was expressing P2X7-R and that receptor expression
alone did not confer an increase in cell conductance, but rather that
receptor occupancy by ATP was an absolute requirement for pore
formation. Reversal of the Cl gradient confirmed that the
preparation was permeabilized and also established that the current was
Cl -selective. Stable expression of P2X7-R
allows us an opportunity to determine the characteristics of the
Ca2+i-activated Cl conductance of the
apical membrane in CF murine tracheal epithelial cells. This novel
protocol for membrane permeabilization (transfection and activation of
P2X7-R) has the further advantage of serving as a
self-contained control for permeabilization. By not exposing the cells
to millimolar basolateral ATP, the cells function as an intact
monolayer, thus the same monolayer preparation can be used for both
non-permeabilized and permeabilized protocols.
We have characterized apical membrane CaCC in these preparations in
terms of ion selectivity and inhibitor sensitivity. As mentioned
earlier, several reports have provided differing characteristics for
the CaCC. We believe that characterization in the CF murine airway
apical membrane will provide the hallmark characteristics for this
channel for subsequent whole cell and single channel analyses. Initial
studies in P2X7-R-permeabilized monolayers (Figs. 2 and 3)
demonstrated a Cl current in response to a gradient that
was generated by partial replacement of the mucosal Cl
with the less permeant anion, gluconate. Although this fundamentally important experiment demonstrates the presence of the apical membrane Cl conductance, it also in fact serves as the first in a
series of ion replacement studies. Although gluconate is often used as an "impermeant" anion, it is really only less permeant than the halide series. Therefore, a bi-ionic solution of Cl and
gluconate can be evaluated for permselectivity based on the magnitude
of the current response and a calculated equilibrium potential. As
observed in Fig. 4, not surprisingly, Cl is more permeant
than gluconate and results in a Cl current from serosal
to mucosal solution. In contrast, when the mucosal Cl is
partially replaced with iodide or bromide, we observed a smaller UTP-induced secretion and a greater shift from the ideal equilibrium potential, suggesting an ion series for this apical Cl
conductance of Cl > I > Br > gluconate . This anion selectivity sequence is somewhat
similar to other reports of Ca2+-activated Cl
channels (14, 41-43) but importantly differs from the selectivity sequence for CFTR (3, 4, 14, 42) or from the CLC superfamily of
Cl channels (44).
Cl channel blockers were investigated to determine a
"sensitivity sequence" for the CaCC channel. Pretreatment of
permeabilized monolayers with the Cl channel blockers was
used to determine a percentage inhibition of the UTP-mediated
Cl current. The rank order of potency for channel
inhibitors appears to be NFA, NPPB ( 90%) > DIDS
( 60%) > glybenclamide ( 40%) tamoxifen, TS-TM
calixarene, and DPC (0-10%). The very low, nearly non-existent effect
of TS-TM calixarene was consistent with previous studies that defined
this compound as a specific inhibitor of the outward rectifying
Cl channel (36). The moderate effect of glybenclamide on
CaCC was a bit surprising, because this sulfonylurea compound was
thought to be fairly specific for K-ATP and CFTR channels (45, 46). In
many studies DIDS is reported to be a highly effective inhibitor of
Ca2+-activated Cl conductance (18-20, 41,
47), and although we observed moderate inhibition, it was not as
effective as NFA. Higher doses of DIDS may generate higher levels of
inhibition, but we are sensitive to the concerns of cross-linking that
are associated with this compound. In our studies NFA was the most
potent inhibitor of CaCC but like many Cl channel
blockers lacks specificity, as it has been shown to also inhibit CFTR
in human airways (47, 48). These studies serve to confirm the notion
that Cl channel blockers are notoriously nonspecific, and
inhibitor studies should be used simply as another characteristic to
define the observed current. That is, an inhibitor order of potency or
sensitivity sequence should serve an analogous function as a halide
permselectivity sequence. The identity of the current should be defined
by a combination of those characteristic sequences rather than any
single effect.
Tamoxifen has recently been shown to have inhibitory effects against
the human ClCA2 channel (32). Interestingly, tamoxifen was without
effect in our CF murine tracheal epithelial cells. Furthermore, we have
not been able to detect the murine homologue of this channel, mClCA1,
by Northern blot analysis in our CF murine tracheal epithelial cells,
suggesting that the apical membrane Ca2+i-activated
Cl conductance is mediated by a thus far unidentified
gene or protein.
We propose to utilize the activation, inhibition, and selectivity
characteristics determined in this study for future experiments studying whole cell currents and single channel properties and ensure
that the channel characteristics are consistent at each level of
investigation. This systematic approach will result in the unambiguous
identification of the murine airway CaCC localized to the apical
membrane. Identification of CaCC along with a determination of regional
distribution within the lung will permit us to develop strategies to
activate CaCC and stimulate Cl and fluid secretion and
thereby ameliorate the dehydration that is foremost in the pathology of
cystic fibrosis.
 |
ACKNOWLEDGEMENTS |
We thank Drs. J. Stutts and B. Grubb
(University of North Carolina) for excellent advice, discussion, and
review of this manuscript. We are especially grateful to Dr. George
Dubyak (Case Western Reserve) for his kind gift of the cDNA for the
P2X7-R. We also thank Dr. John Olsen (University of North
Carolina) for assistance with retroviral expression of the
P2X7-R. Thanks also to Drs. B. Bridges and A. Singh
(University of Pittsburgh) for the generous gift of TS-TM calixarene.
 |
FOOTNOTES |
*
This work was supported by Grant 99PO from the Cystic
Fibrosis Foundation and Grant HL62564 from the National Institutes of Health (both to S. E. G.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: CF/PRT Center & Dept.
of Pediatrics, University of North Carolina, Chapel Hill, NC 27599. Tel.: 919-966-7058; Fax: 919-966-7524; E-mail: sgabriel@ med.unc.edu.
Published, JBC Papers in Press, August 15, 2000, DOI 10.1074/jbc.M004953200
 |
ABBREVIATIONS |
The abbreviations used are:
CF, cystic fibrosis;
P2X7-R, P2X7 purinoreceptor;
CaCC, Ca2+i-activated Cl conductance;
CFTR, cystic fibrosis transmembrane conductance regulator;
KBR, Krebs
bicarbonate Ringer solution;
NFA, niflumic acid;
NPPB, 5-nitro-2-(3-phenylpropylamino)benzoic acid;
DIDS, 4,4'-diisothiocyanostilbene-2,2'-disulfonate;
DPC, diphenlyamine-2-carboxylate;
TS-TM calixarene, p-tetra-sulfonato-tetra-methoxy-calix[4]arene.
 |
REFERENCES |
| 1.
|
Boucher, R. C.
(1994)
Am. J. Respir. Crit. Care Med.
150,
581-593
|
| 2.
|
Boucher, R. C.
(1994)
Am. J. Respir. Crit. Care Med.
150,
271-281
|
| 3.
|
Kartner, N.,
Hanrahan, J. W.,
Jensen, T. J.,
Naismith, A. L.,
Sun, S.,
Ackerley, C. A.,
Reyes, E. F.,
Tsui, L. C.,
Rommens, J. M.,
Bear, C. E.,
and Riordan, J. R.
(1991)
Cell
64,
681-691
|
| 4.
|
Bear, C. E.,
Li, C.,
Kartner, N.,
Bridges, R. J.,
Jensen, T. J.,
Ramjeesingh, M.,
and Riordan, J. R.
(1992)
Cell
68,
809-818
|
| 5.
|
Clarke, L. L.,
Paradiso, A. M.,
and Boucher, R. C.
(1992)
Am. J. Physiol.
263,
C1190-C1199
|
| 6.
|
Noah, T. L.,
Paradiso, A. M.,
Madden, M. C.,
McKinnon, K. P.,
and Devlin, T. B.
(1991)
Am. J. Respir. Cell Mol. Biol.
5,
484-492
|
| 7.
|
Clarke, L. L.,
Paradiso, A. M.,
Mason, S. J.,
and Boucher, R. C.
(1992)
Am. J. Physiol.
262,
C644-C655
|
| 8.
|
Paradiso, A. M.,
Cheng, E. H. C.,
and Boucher, R. C.
(1991)
Am. J. Physiol.
261,
L63-L69
|
| 9.
|
Mason, S. J.,
Paradiso, A. M.,
and Boucher, R. C.
(1991)
Br. J. Pharmacol.
103,
1649-1656
|
| 10.
|
Knowles, M. R.,
Clarke, L. L.,
and Boucher, R. C.
(1991)
N. Engl. J. Med.
325,
533-538
|
| 11.
|
Clarke, L. L.,
and Boucher, R. C.
(1992)
Am. J. Physiol.
263,
C348-C356
|
| 12.
|
Willumsen, N. J.,
and Boucher, R. C.
(1989)
Am. J. Physiol.
256,
C226-C233
|
| 13.
|
Boucher, R. C.,
Cheng, E. H. C.,
Paradiso, A. M.,
Stutts, M. J.,
Knowles, M. R.,
and Earp, H. S.
(1989)
J. Clin. Invest.
84,
1424-1431
|
| 14.
|
Anderson, M. P.,
and Welsh, M. J.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
6003-6007
|
| 15.
|
Snouwaert, J. N.,
Brigman, K. K.,
Latour, A. M.,
Malouf, N. N.,
Boucher, R. C.,
Smithies, O.,
and Koller, B. H.
(1992)
Science
257,
1083-1088
|
| 16.
|
Grubb, B. R.,
Vick, R. N.,
and Boucher, R. C.
(1994)
Am. J. Physiol.
266,
C1478-C1483
|
| 17.
|
Devor, D. C.,
and Pilewski, J. M.
(199)
Am. J. Physiol.
276,
C827-C837
|
| 18.
|
Egan, M.,
Flotte, T.,
Afione, S.,
Solow, R.,
Zeitlin, P. L.,
Carter, B. J.,
and Guggino, W. B.
(1992)
Nature
358,
581-584
|
| 19.
|
Hanrahan, J. W.,
and Tabcharani, J. A.
(1989)
Ann. N. Y. Acad. Sci.
574,
30-43
|
| 20.
|
Tabcharani, J. A.,
and Hanrahan, J. W.
(1991)
Am. J. Physiol.
261,
G992-G999
|
| 21.
|
Hanrahan, J. W.,
and Tabcharani, J. A.
(1990)
J. Membr. Biol.
116,
65-77
|
| 22.
|
Tabcharani, J. A.,
Jensen, T. J.,
Riordan, J. R.,
and Hanrahan, J. W.
(1989)
J. Membr. Biol.
112,
109-122
|
| 23.
|
McCann, J. D.,
Li, M.,
and Welsh, M. J.
(1989)
J. Gen. Physiol.
94,
1015-1036
|
| 24.
|
McCann, J. D.,
Bhalla, R. C.,
and Welsh, M. J.
(1989)
Am. J. Physiol.
257,
L116-L124
|
| 25.
|
Ishikawa, T.,
and Cook, D. I.
(1993)
J. Membr. Biol.
135,
261-271
|
| 26.
|
Duszyk, M.,
and Man, S. F. P.
(1992)
Biophys. J.
61,
583-587
|
| 27.
|
Morris, A. P.,
and Frizzell, R. A.
(1993)
Am. J. Physiol.
264,
C968-C976
|
| 28.
|
Kunzelmann, K.,
Kubitz, R.,
Grolik, M.,
Warth, R.,
and Greger, R.
(1992)
Pfluegers Arch.
421,
238-246
|
| 29.
|
Gruber, A. D.,
Elble, R. C.,
Ji, H. L.,
Schreur, K. D.,
Fuller, C. M.,
and Pauli, B. U.
(1998)
Genomics
54,
200-214
|
| 30.
|
Gandhi, R.,
Elble, R. C.,
Gruber, A. D.,
Schreur, K. D.,
Ji, H. L.,
Fuller, C. M.,
and Pauli, B. U.
(1998)
J. Biol. Chem.
273,
32096-32101
|
| 31.
|
Romio, L.,
Musante, L.,
Cinti, R.,
Seri, M.,
Moran, O.,
Zegarra-Moran, O.,
and Galietta, L. J. V.
(1999)
Gene
228,
181-188
|
| 32.
|
Gruber, A. D.,
Schreur, K. D.,
Ji, H. L.,
Fuller, C. M.,
and Pauli, B. U.
(1999)
Am. J. Physiol.
276,
C1261-C1270
|
| 33.
| Gabriel, S. E., Thomas, E. J., Makhlina, M., Hardy, S. P., and Lethem, M. I. (1999) Am. J. Physiol., in
press
|
| 34.
|
Humphreys, B. D.,
Virginio, C.,
Suprenant, A.,
Rice, J.,
and Dubyak, G. R.
(1998)
Mol. Pharmacol.
54,
22-32
|
| 35.
|
Rassendren, F.,
Buell, G. N.,
Virginio, C.,
Collo, G.,
North, A.,
and Surprenant, A.
(1997)
J. Biol. Chem.
272,
5482-5486
|
| 36.
|
Singh, A. K.,
Venglarik, C. J.,
and Bridges, R. J.
(1995)
Kidney Int.
48,
985-993
|
| 37.
|
Illek, B.,
Tam, A. W.,
Fischer, H.,
and Machen, T. E.
(1999)
Pfluegers Arch.
437,
812-822
|
| 38.
|
Sheppard, D. N.,
and Robinson, K. A.
(1997)
J. Physiol. (Lond.)
503,
333-346
|
| 39.
|
Adler, E. M.,
Augustine, G. J.,
Duffy, S. N.,
and Charlton, M. P.
(1991)
J. Neurosci.
11,
1496-1507
|
| 40.
|
Nichols, R. A.,
and Suplick, G. R.
(1996)
Neurosci. Lett.
211,
135-137
|
| 41.
|
Stutts, M. J.,
Fitz, J. G.,
Paradiso, A. M.,
and Boucher, R. C.
(1994)
Am. J. Physiol.
267,
C1442-C1451
|
| 42.
|
Cliff, W. H.,
and Frizzell, R. A.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
4956-4960
|
| 43.
|
Hwang, T. H.,
Schwiebert, E. M.,
and Guggino, W. B.
(1996)
Am. J. Physiol.
270,
C1611-C1623
|
| 44.
|
Lorenz, C.,
Pusch, M.,
and Jentsch, T. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
13362-13366
|
| 45.
|
Sheppard, D. N.,
and Welsh, M. J.
(1992)
J. Gen. Physiol.
100,
573-591
|
| 46.
|
Schultz, B. D.,
DeRoos, A. D. G.,
Venglarik, C. J.,
Singh, A. K.,
Frizzell, R. A.,
and Bridges, R. J.
(1996)
Am. J. Physiol.
271,
L192-L200
|
| 47.
|
Gabriel, S. E.,
Boucher, R. C.,
and Stutts, M. J.
(1993)
Pediatr. Pulmonol.
9(Suppl.),
223-224
|
| 48.
|
Zegarra-Moran, O.,
Sacco, O.,
Romano, L.,
Rossi, G. A.,
and Galietta, L. J. V.
(1997)
J. Membr. Biol.
156,
297-305
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Yang, J. Reece, S. E. Gabriel, and S. B. Shears
Apical localization of ITPK1 enhances its ability to be a modifier gene product in a murine tracheal cell model of cystic fibrosis
J. Cell Sci.,
April 1, 2006;
119(7):
1320 - 1328.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R. Grubb, T. D. Rogers, P. C. Diggs, R. C. Boucher, and L. E. Ostrowski
Culture of murine nasal epithelia: model for cystic fibrosis
Am J Physiol Lung Cell Mol Physiol,
February 1, 2006;
290(2):
L270 - L277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Verhoef, S. B. Kertesy, K. Lundberg, J. M. Kahlenberg, and G. R. Dubyak
Inhibitory Effects of Chloride on the Activation of Caspase-1, IL-1{beta} Secretion, and Cytolysis by the P2X7 Receptor
J. Immunol.,
December 1, 2005;
175(11):
7623 - 7634.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Loewen and G. W. Forsyth
Structure and Function of CLCA Proteins
Physiol Rev,
July 1, 2005;
85(3):
1061 - 1092.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Zsembery, J. A. Fortenberry, L. Liang, Z. Bebok, T. A. Tucker, A. T. Boyce, G. M. Braunstein, E. Welty, P. D. Bell, E. J. Sorscher, et al.
Extracellular Zinc and ATP Restore Chloride Secretion across Cystic Fibrosis Airway Epithelia by Triggering Calcium Entry
J. Biol. Chem.,
March 12, 2004;
279(11):
10720 - 10729.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Bertrand, H. Danahay, C. T. Poll, C. Laboisse, U. Hopfer, and R. J. Bridges
Niflumic acid inhibits ATP-stimulated exocytosis in a mucin-secreting epithelial cell line
Am J Physiol Cell Physiol,
February 1, 2004;
286(2):
C247 - C255.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Eggermont
Calcium-activated Chloride Channels: (Un)known, (Un)loved?
Proceedings of the ATS,
January 1, 2004;
1(1):
22 - 27.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Maminishkis, S. Jalickee, S. A. Blaug, J. Rymer, B. R. Yerxa, W. M. Peterson, and S. S. Miller
The P2Y2 Receptor Agonist INS37217 Stimulates RPE Fluid Transport In Vitro and Retinal Reattachment in Rat
Invest. Ophthalmol. Vis. Sci.,
November 1, 2002;
43(11):
3555 - 3566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Tarran, M. E. Loewen, A. M. Paradiso, J. C. Olsen, M. A. Gray, B. E. Argent, R. C. Boucher, and S. E. Gabriel
Regulation of Murine Airway Surface Liquid Volume by CFTR and Ca2+-activated Cl- Conductances
J. Gen. Physiol.,
August 26, 2002;
120(3):
407 - 418.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Loewen, S. E. Gabriel, and G. W. Forsyth
The calcium-dependent chloride conductance mediator pCLCA1
Am J Physiol Cell Physiol,
August 1, 2002;
283(2):
C412 - C421.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kunzelmann and M. Mall
Electrolyte Transport in the Mammalian Colon: Mechanisms and Implications for Disease
Physiol Rev,
January 1, 2002;
82(1):
245 - 289.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|